Critical Challenges and Compelling Questions for COPD

Chronic Obstructive Pulmonary Disease (COPD) is the third-leading cause of death in the United States. Despite its significant impact on the World’s population, mush about the disease remains poorly understood. Further research is crucial to inform healthcare providers about pathogenesis, risk factors, and better therapeutic approaches. This session will identify gaps in our current knowledge base, describe recent progress in the field of COPD research, and outline strategies to help answer compelling questions relevant to this disease. 

This course is an edited and enhanced recording of the ATS 2022 International Conference session with the same name.

Grant Support: This educational module is supported by an independent medical educational grant from AstraZeneca LP.

Target Audience

Clinicians (physicians, nurses, fellows, residents), researchers, administrators, and policymakers: anyone involved in the delivery of care and the science of patients with COPD

Learning Objectives

After successfully completing this module, learners will be able to:
• Discuss novel concepts in disease pathogenesis, health disparities, and therapeutic strategies
• Identify critical areas of future COPD research priorities for the upcoming decade
• Describe the challenges for optimal implementation of COPD research in an effort to impact local and national treatment outcomes

Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit(s)
    The American Thoracic Society designates this for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.50 Participation
Publication Date: 
Credit Expires: 
Ravi Kalhan, MD, MS. Director, Asthma and COPD ProgramNorthwestern University Feinberg School of MedicinePresenterGlaxoSmithKline: Advisory Committee for promotional purpose
AstraZeneca: Advisory Committee for promotional purpose
CVS Caremark: Consultant
Michael Bradley Drummond, MHS, MD, ATSFAssociate Professor of MedicineThe University of North Carolina at Chapel HillPresenterVerona: Consultant
Boehringer Ingelheim: Consultant; Research - investigator initiated
Teva: Consultant; Research - investigator initiated
Midmark: Consultant; Research - investigator initiated
Optimum: Consultant
GlaxoSmithKline: Consultant
Polarean: Consultant
National Institutes of Health: Research - investigator initiated
Christine M. Freeman, PhDAssistant Research ProfessorUniversity of Michigan, Ann ArborPresenterNONE
Stefanie Krick, MD, PhDAssistant Professor, Division of Pulmonary, Allergy and Critical Care MedicineUniversity of Alabama at BirminghamPresenterNONE
Lisa Postow, PhDProgram Director, National Heart, Lung, and Blood InstituteNational Institutes of HealthPresenterNONE

Accreditation Statement

The American Thoracic Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Disclosure Declaration

It is the policy of the ATS to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. As an accredited CME provider, the ATS requires that its planners, reviewers and presenters comply with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. The ATS also requires specific disclosure of relationships with companies and organizations associated with tobacco or cannabis and prohibits or limits participation of faculty in official ATS activities, including CME, if any tobacco industry relationship or some types of cannabis industry relationships are present. To see the most recent policies regarding potential conflicts of interest as well as the mechanisms to resolve such conflicts, press the COI Policy link below.

This educational activity may include discussion of unapproved uses of a drug, product, or device. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Instructions to Receive Credit

To earn credit for this course, follow these instructions:

  1. Launch and complete all modules by viewing every page in the module.
  2. After you complete the module(s), the post test will become available. You must pass the post these with a 70% score or better.
  3. Complete the Course Evaluation.
  4. Once you complete the modules, pass the post test and complete the evaluation, the system will grant you credit.
  5. To view your transcript and print your certificate, go to the My Account drop-down list. Then select Transcript.

Available Credit

  • 1.50 AMA PRA Category 1 Credit(s)
    The American Thoracic Society designates this for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.50 Participation
Please login or register to take this course.


To start this learning activity, press the Take Activity button. Then follow the on-screen instructions.

The system keeps track of your progress. If you close the activity and resume it later, it will re-start where you left off.